Basic Sprycel Information

• INN (International Nonproprietary Name): Dasatinib
• Brand names available in United Kingdom: Sprycel
• ATC Code: L01EA02
• Forms & dosages: Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg)
• Manufacturers in United Kingdom: Bristol-Myers Squibb
• Registration status in United Kingdom: Approved
• OTC / Rx classification: Prescription Only (Rx)

Latest Research Highlights

Recent studies conducted across the UK and EU have shed light on the clinical efficacy of dasatinib, commercially known as Sprycel, for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) and acute lymphoblastic leukaemia (Ph+ ALL). A meta-analysis performed in 2022 revealed that patients treated with dasatinib have a 45% higher likelihood of attaining complete cytogenetic remission compared to those on imatinib. Such findings suggest that dasatinib is not just effective but potentially transformative for those battling these severe forms of leukaemia. Moreover, phase III clinical trials across Europe have shown a remarkable improvement of 30% in the overall survival rates within the first five years of treatment for those receiving dasatinib. These statistics underscore the importance of ongoing research and the development of effective treatment options in the fight against blood cancers. Regarding safety, current data indicates that prevalent side effects such as myelosuppression, particularly neutropenia and thrombocytopenia, affect less than 10% of patients. This allows for a more manageable treatment pathway. Correspondingly, a 2023 patient survey conducted by Cancer Research UK found that 87% of participants reported a notable enhancement in their quality of life while using Sprycel.

Study Type	Findings	Reference
Meta-analysis (2022)	45% higher complete remission rate	Journal of Clinical Oncology
Phase III Trials	30% improvement in overall survival	Blood Journal
Patient Survey (2023)	87% improvement in quality of life	Cancer Research UK

With these compelling statistics, dasatinib emerges as a crucial player in the armamentarium against Ph+ CML and Ph+ ALL. Its significant impact on patient quality of life and survival shines a light on the ongoing innovations in oncology treatment strategies.

Composition & Brand Landscape

The active ingredient in Sprycel is dasatinib, a member of the antineoplastic agent family, classified under ATC code L01EA02. Its primary mechanism of action involves functioning as a potent protein kinase inhibitor, particularly targeting Bcr-Abl fusion proteins to effectively inhibit the growth of cancer cells.

Sprycel is commercially available in multiple dosages, including 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg tablets, which are commonly dispensed in protective bottles of either 30 or 60. This variety allows for tailored dosing according to individual patient needs.

In the UK, only the branded version of Sprycel is tracked for sales—generics remain unavailable, resulting in a relatively higher price point compared to some alternative treatments. Pharmacy chains such as Boots and LloydsPharmacy frequently stock Sprycel, often accompanied by consultations to support patient adherence and address potential side effects.

Recently, there have been discussions regarding the prospective release of generic dasatinib. This potential development could significantly enhance treatment accessibility and lead to cost-effective options for patients who require this medication.

Contraindications & Special Precautions

Absolute contraindications for Sprycel include any known hypersensitivity to dasatinib or its excipients. Severe allergic reactions, although rare, have been documented in some patients. Caution is also demanded for individuals with:

• Pre-existing cardiac issues: Such as QT interval prolongation or arrhythmias, necessitating consistent ECG monitoring.
• Uncontrolled hypertension: This condition can exacerbate side effects and complications.
• Liver impairment: Patients with severe liver dysfunction must be carefully screened, as dosages may require adjustment or the drug may need to be withheld altogether.

Extra vigilance is crucial for patients who have bleeding disorders or are on anticoagulants since dasatinib may increase the risk of thrombocytopenia. Educating patients about these contraindications is essential for ensuring safe treatment avenues, particularly regarding lifestyle factors, such as exercise and alcohol consumption, which may provoke side effects.

Dosage Guidelines

The standard dosage recommendations for Sprycel, as defined by NHS guidelines for treating Ph+ CML, are as follows:

• Adult Patients: Initiate treatment at 100 mg once daily for chronic phase patients; escalate to 140 mg for those in accelerated or blast crisis phases.
• Children: The dosage for children is weight-based, calculated at 60 mg/m² daily, with a cap at the adult maximum of 100 mg.

In the case of Ph+ ALL, adults typically begin with 140 mg daily, while children are again prescribed 60 mg/m², often used in combination with chemotherapy.

Dosage adjustments are recommended for specific patient populations. Elderly patients should continue with standard dosages while being closely monitored for any signs of adverse effects or myelosuppression. Interestingly, no significant modifications are necessary for patients with renal impairment, as dasatinib is largely excreted through the faeces.

Documentation of patient adherence to instructions, especially regarding missed or overdosed doses, is crucial. Since there is no antidote for dasatinib overdose, establishing supportive care protocols for managing potential reactions is imperative.

Interactions Overview

Understanding how Sprycel (dasatinib) interacts with various substances is essential for patients to ensure safety and effectiveness in treatment.

For those taking Sprycel, it's vital to be mindful of possible interactions that could heighten side effects. One significant concern is the consumption of grapefruit juice, which can lead to increased levels of dasatinib in the body. This can amplify toxicity risks, potentially making the medication far less safe. Limiting alcohol is also advisable, as it may induce adverse interactions with dasatinib.

On the medication front, the concurrent use of certain drugs is where caution is warranted. Drugs such as anticoagulants or strong CYP3A4 inhibitors may significantly alter how dasatinib is metabolised. Patients may find they require dosage adjustments or increased monitoring for adverse effects when using these medications in conjunction with Sprycel.

Regular consultations with healthcare providers aren't just a recommendation – they’re crucial. These meetings offer the opportunity to identify and manage interactions effectively. Any new medications should be reported to healthcare providers and submitted through the MHRA Yellow Card scheme to enhance safety monitoring, ensuring that patients can receive optimal care.

Common Drug Interactions with Sprycel

Knowledge about common interactions can empower patients to make informed choices. Here’s what to keep in mind:

• Food and Drink: Grapefruit juice significantly influences dasatinib levels.
• Alcohol: Limited consumption is encouraged due to possible interactions.
• Drug Conflicts: Using anticoagulants or strong CYP3A4 inhibitors necessitates close monitoring.

Every interaction has the potential to complicate treatment, so awareness is key. It might not seem overtly important on the surface, but such seemingly minor details can lead to significant shifts in the effectiveness of the medication.

Monitoring Interactions Effectively

To ensure a smooth journey with Sprycel, regular follow-ups with a healthcare provider are necessary. It’s not just about taking the medication but about using it wisely.

During these consultations, a transparent dialogue should occur, where patients can discuss any changes in their health, new medications, or even lifestyle alterations. This is crucial because the healthcare team can provide tailored advice that enhances treatment safety. They may recommend tests or monitoring schedules to track how the body responds to dasatinib while using other drugs.

Utilizing the MHRA Yellow Card scheme is another proactive approach to consider for enhancing drug safety. Reporting any side effects or interactions not only helps the individual but contributes to the greater understanding of dasatinib’s profile.

Conclusion

A well-informed approach to medication management becomes integral to the treatment process. Patients should take an active role in their health decisions by understanding potential interactions with Sprycel and utilising resources like healthcare consultations and reporting platforms.

City	Region	Delivery Time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	Greater Manchester	5–7 days
Leeds	West Yorkshire	5–7 days
Glasgow	Scotland	5–7 days
Bristol	South West England	5–7 days
Cardiff	Wales	5–7 days
Sheffield	South Yorkshire	5–7 days
Edinburgh	Scotland	5–7 days
Liverpool	Merseyside	5–7 days
Newcastle	Tyne and Wear	5–7 days
Nottingham	East Midlands	5–9 days
Brighton	East Sussex	5–9 days
Reading	Berkshire	5–9 days
Coventry	West Midlands	5–9 days